KP-1077 is a small molecule commercialized by KemPharm, with a leading Phase II program in Hypersomnia. According to Globaldata, it is involved in 3 clinical trials, of which 1 was completed, 1 is ongoing, and 1 is planned. GlobalData uses proprietary data and analytics to provide a complete picture of KP-1077’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for KP-1077 is expected to reach an annual total of $21 mn by 2035 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

KP-1077 Overview

KP-1077 is under development for the treatment of idiopathic hypersomnia (IH) and narcolepsy type I and II. The drug candidate is a prodrug of serdexmethylphenidate (SDX), developed based on ligand-activated therapy (LAT) platform. It is administered through oral route.

KemPharm Overview

KemPharm is a clinical-stage specialty pharmaceutical company that offers discovery and development of proprietary new molecular entity prodrugs. The company’s product pipeline includes KP415, KP484 methylphenidate drug for the treatment of attention deficit hyperactivity disorder (ADHD); and KP879 drugs for the treatment of stimulant use disorder. KemPharm uses ligand activated therapy (LAT) a platform technology to produce new molecular entity prodrugs. The company offers its products in the therapeutic areas such as Attention deficit hyperactivity disorder (ADHD), pain and other central nervous system indications. KemPharm is headquartered in Florida, the US.

The company reported revenues of (US Dollars) US$28.7 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$13.3 million in FY2020. The operating loss of the company was US$8.4 million in FY2021, compared to an operating loss of US$5.6 million in FY2020. The net loss of the company was US$8.6 million in FY2021, compared to a net loss of US$12.8 million in FY2020. The company reported revenues of US$2.9 million for the third quarter ended September 2022, compared to a revenue of US$1.3 million the previous quarter.

For a complete picture of KP-1077’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.